Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

136
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
136
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

160
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
160

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Improving Machine Learning Classification Predictions through SHAP and Features Analysis Interpretation.

Journal of chemical information and modeling·2025
Same author

Structure-Based Discovery of Hsp90/HDAC6 Dual Inhibitors Targeting Aggressive Prostate Cancer.

Journal of medicinal chemistry·2025
Same author

Exploring Biological Targets of Magnolol and Honokiol and their Nature-Inspired Synthetic Derivatives: In Silico Identification and Experimental Validation of Estrogen Receptors.

Journal of natural products·2024
Same author

Quantitative live cell imaging of a tauopathy model enables the identification of a polypharmacological drug candidate that restores physiological microtubule interaction.

Nature communications·2024
Same author

Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers.

Molecules (Basel, Switzerland)·2024
Same author

Discovery of a Potent Dual Inhibitor of Aromatase and Aldosterone Synthase.

ACS pharmacology & translational science·2023

相关实验视频

Updated: Jun 14, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K

寻找具有抗前列腺癌活性的新型HDAC6 / Hsp90双抑制剂:在体查和体外评估中.

Luca Pinzi1, Silvia Belluti1, Isabella Piccinini1

  • 1Department of Life Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi 103, 41125 Modena, Italy.

Pharmaceuticals (Basel, Switzerland)
|August 29, 2024
PubMed
概括

研究人员选化合物对HDAC6和HSP90的双抑制治疗晚期前列腺癌 (PCA). 虽然化合物抑制了HDAC6并降低了PCA细胞生长,但没有观察到Hsp90的抑制,这表明了优化潜力.

关键词:
在 HDAC6 中.在Hsp90中,它是Hsp90的.药物设计 药物设计前列腺癌是前列腺癌.虚拟选 虚拟选 虚拟选

更多相关视频

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.5K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K

相关实验视频

Last Updated: Jun 14, 2025

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS
09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

8.5K
Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.5K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K

科学领域:

  • 在瘤学瘤学.
  • 药用化学 医学化学
  • 生物化学 生物化学

背景情况:

  • 由于药物耐药性,前列腺癌 (PCA) 对晚期癌症的治疗选择有限.
  • 组合抑制基因素脱乙酶6 (HDAC6) 和热冲击蛋白90 (Hsp90) 提供了对PCA的潜在协同效应.
  • HDAC6和Hsp90在调节癌细胞过程中起着至关重要的作用.

研究的目的:

  • 确定针对HDAC6和Hsp90的新型双抑制剂,用于晚期前列腺癌治疗.
  • 对商业化合物进行潜在的双重抑制剂的in silico虚拟选.
  • 评估已识别的化合物对PCA细胞的体外疗效.

主要方法:

  • 商业复合图书馆进行了广泛的in silico虚拟选.
  • 在体外酶抑制对复合HDAC6.6的测定.
  • 使用LNCaP和PC-3前列腺癌细胞系的抗增殖试验.

主要成果:

  • 一组化合物显示出显著的HDAC6抑制活性.
  • 确定的化合物对LNCaP和PC-3细胞表现出抗增殖作用.
  • 没有化合物显示出显著的Hsp90抑制,但具有与已知的Hsp90抑制剂的结构相似之处.

结论:

  • 这些已识别的化合物是开发新型HDAC6/Hsp90双调节器的有希望的起点.
  • 进一步优化药物化学是有必要的,以增强Hsp90抑制活性.
  • 这些优化的化合物可以为晚期前列腺癌提供改进的治疗策略.